Since PI3K-AKT-mTOR activation is responsible for an increase in cell survival, cell proliferation and, is associated with an activation of DNA repair, we speculated that the combination of PARP and PI3K-inhibitors could be beneficial in endometrial cancer. The gene discussed is PARP1; the disease is endometrial cancer.